Balance Sheet
Cash Flow Statement
Beginning Cash BalanceChange in Account PayablesCurrent DebtGains from Sales and DivestituresNet Debt Issuances and RepaymentsNon-cash ItemsOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Beginning Cash Balance: 2017-2025

Historic Beginning Cash Balance for China SXT Pharmaceuticals (SXTC) over the last 9 years, with Mar 2025 value amounting to $12.0 million.

  • China SXT Pharmaceuticals' Beginning Cash Balance rose 50.11% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.1 million, marking a year-over-year increase of 50.11%. This contributed to the annual value of $12.0 million for FY2025, which is 30.61% down from last year.
  • Latest data reveals that China SXT Pharmaceuticals reported Beginning Cash Balance of $12.0 million as of FY2025, which was down 30.61% from $17.4 million recorded in FY2024.
  • Over the past 5 years, China SXT Pharmaceuticals' Beginning Cash Balance peaked at $17.4 million during FY2024, and registered a low of $7.3 million during FY2021.
  • Over the past 3 years, China SXT Pharmaceuticals' median Beginning Cash Balance value was $15.6 million (recorded in 2023), while the average stood at $15.0 million.
  • Per our database at Business Quant, China SXT Pharmaceuticals' Beginning Cash Balance spiked by 83.33% in 2022 and then plummeted by 30.61% in 2025.
  • China SXT Pharmaceuticals' Beginning Cash Balance (Yearly) stood at $7.3 million in 2021, then soared by 83.33% to $13.4 million in 2022, then grew by 16.55% to $15.6 million in 2023, then grew by 11.51% to $17.4 million in 2024, then plummeted by 30.61% to $12.0 million in 2025.